Deciphering tissue-induced Klebsiella pneumoniae lipid A structure by Llobet, Enrique et al.
Deciphering tissue-induced Klebsiella pneumoniae
lipid A structure
Enrique Llobeta,b,c,1, Verónica Martínez-Molinera,b,c,1, David Morantaa,b,c, Käthe M. Dahlströmd, Verónica Regueiroa,b,c,
Anna Tomása,b,c, Victoria Canoa,b,c, Camino Pérez-Gutiérrezb,c, Christian G. Franke, Helena Fernández-Carrascoe,
José Luis Insuae, Tiina A. Salminend, Junkal Garmendiac,f, and José A. Bengoecheae,g,2
aDepartment of Microbial Pathogenesis, Institut d’Investigació Sanitària de Palma, 07120 Palma, Spain; bLaboratory Microbial Pathogenesis, Fundació
d’Investigació Sanitària de les Illes Balears, 07210 Bunyola, Spain; cCentro de Investigación Biomédica en Red Enfermedades Respiratorias, 028029 Madrid,
Spain; dStructural Bioinformatics Laboratory, Department of Biosciences, Åbo Akademi University, FIN-20520 Turku, Finland; eCentre for Infection and
Immunity, Queen’s University, BT9 7AE Belfast, United Kingdom; fInstituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas–
Universidad Pública de Navarra–Gobierno de Navarra, 31192 Navarra, Spain; and gConsejo Superior de Investigaciones Científicas, 28006 Madrid, Spain
Edited by Ralph R. Isberg, Howard Hughes Medical Institute/Tufts University School of Medicine, Boston, MA, and approved October 13, 2015 (received for
review May 5, 2015)
The outcome of an infection depends on host recognition of the
pathogen, hence leading to the activation of signaling pathways
controlling defense responses. A long-held belief is that the modi-
fication of the lipid A moiety of the lipopolysaccharide could help
Gram-negative pathogens to evade innate immunity. However,
direct evidence that this happens in vivo is lacking. Here we report
the lipid A expressed in the tissues of infected mice by the human
pathogen Klebsiella pneumoniae. Our findings demonstrate that
Klebsiella remodels its lipid A in a tissue-dependent manner. Lipid A
species found in the lungs are consistent with a 2-hydroxyacyl-
modified lipid A dependent on the PhoPQ-regulated oxygenase
LpxO. The in vivo lipid A pattern is lost in minimally passaged bac-
teria isolated from the tissues. LpxO-dependent modification reduces
the activation of inflammatory responses and mediates resistance to
antimicrobial peptides. An lpxOmutant is attenuated in vivo thereby
highlighting the importance of this lipid A modification in Klebsiella
infection biology. Colistin, one of the last options to treat multidrug-
resistant Klebsiella infections, triggers the in vivo lipid A pattern.
Moreover, colistin-resistant isolates already express the in vivo lipid
A pattern. In these isolates, LpxO-dependent lipid A modification
mediates resistance to colistin. Deciphering the lipid A expressed in
vivo opens the possibility of designing novel therapeutics targeting
the enzymes responsible for the in vivo lipid A pattern.
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The lipopolysaccharide (LPS) contains a molecular pattern rec-ognized by the innate immune system thereby initiating host
defense responses. Innate host identification of lipid A relies on
the inability of bacteria to alter this component dramatically. The
canonical lipid A structure activating innate LPS receptors is
expressed by Escherichia coli K12 and consists of a β(1′–6)-linked
disaccharide of glucosamine phosphorylated at the 1 and 4′ posi-
tions, with positions 2, 3, 2′, and 3′ acylated with R-3-hydroxy-
myristoyl groups (3-OH-C14). The 2′ and 3′ R-3-hydroxymyristoyl
groups are acylated with laureate (C12) and myristate (C14) by
the action of the acyltransferases LpxL and LpxM, respectively
(1). Although the enzymes required to synthesize lipid A are
conserved throughout all Gram-negative bacteria, there is het-
erogeneity of the lipid A structure among Gram-negative bacteria.
This is due to differences in the type and length of fatty acids,
in the presence of chemical moieties, or even in the removal
of groups such as phosphates or fatty acids from lipid A (1–3).
Well-characterized modifications include the addition of phos-
phoethanolamine (4), 4-aminoarabinose (5), palmitate (6), and
hydroxylation by the Fe2+/α-ketoglutarate-dependent dioxygenase
enzyme (LpxO) (7–9).
In vitro evidence demonstrates that increased natural diversity
or heterogeneity within lipid A can produce dramatic host re-
sponses. It has been hypothesized that modification of lipid A in
response to different host microenvironments helps pathogens to
survive in the hostile host by camouflaging the pathogen from host
immune detection, promoting antimicrobial peptide resistance
and by altering outer membrane properties (3, 10, 11). However,
direct evidence showing that bacteria remodel their lipid A in vivo
is lacking.
Here, we set out to determine lipid A expressed in vivo by
Klebsiella pneumoniae. This pathogen has been singled out by the
World Health Organization as a public health threat due to the
emergence of drug-resistant strains. Infections caused by carbape-
nem-resistant K. pneumoniae isolates are responsible for high rates
of morbidity and mortality and they represent a major therapeutic
challenge, especially when the isolates are also resistant to colistin,
which is the last-line antibiotic for treating K. pneumoniae infec-
tions (12). The evidence presented in this article demonstrates that
Gram-negative bacteria do remodel their lipid A in vivo and that
these in vivo-induced lipid A changes contribute to virulence by
counteracting innate immune defenses.
Results
Analysis of K. pneumoniae Lipid A in Vivo. To determine the lipid A
expressed in vivo by wild-type K. pneumoniae 52145 (hereafter
Kp52145), mice were infected intranasally, and lipid A was extracted
from bronchoalveolar lavage fluid (BALF) using an ammonium
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hydroxide/isobutyric acid method and subjected to negative
ion matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry analysis (13).The number of
bacteria recovered from the lungs of infected mice was between
106 and 107 cfu per gram of tissue at 24 h postinfection. In BALFs
from PBS mock-infected mice, the background noise was between
5 and 100 arbitrary units, which corresponds to an overall de-
tection limit at a relative abundance of approximately 10% (Fig.
1A; red spectrum). Two ions of mass-to-charge ratios (m/z) 1,840
and m/z 1,866 were detected in BALFs from infected mice (Fig.
1A). Similar ions were detected when lipid A was extracted using
the TRI Reagent method (14) (SI Appendix, Fig. S1A), when lung
homogenates were analyzed (SI Appendix, Fig. S1B), and at 48 h
postinfection (SI Appendix, Fig. S1C). Consistent with previous
reports (15, 16), the lipid A extracted from Kp52145 grown in
lysogeny broth (LB) contained the hexaacylated species m/z 1,824
corresponding to two glucosamines, two phosphates, four
R-3-hydroxymyristoyl primary acyl chains, and two myristates
(C14) as secondary acyl chains (Figs. 1B and 2). The other peak
(m/z 1,840) may represent a hexaacylated lipid A containing two
glucosamines, two phosphates, four R-3-hydroxymyristoyl primary
acyl chains, one myristate (C14), and one 2-hydroxymyristate
(C14:OH) (Figs. 1B and 2). The lipid A of bacteria isolated from
the lung homogenates was not exactly the same as that found in
vivo (Fig. 1C), whereas the lipid A of bacteria passaged twice on
LB agar plates (Fig. 1D) was identical to the lipid A from Kp52145
grown in LB (Fig. 1B).
Speciesm/z 1,866, not detected in the lipid A from Klebsiella grown
in LB, has been previously found in the lipid A from aK. pneumoniae
lpxMmutant (16). Klebsiella LpxM catalyzes the addition of myristate
(C14) to the 3′ R-3-hydroxymyristoyl (16). As expected, the lipid A
species detected in the Kp52145 lpxM mutant grown in LB were m/z
1,614 and m/z 1,630, which are consistent with the lack of myristate
(C14) from speciesm/z 1,824 andm/z 1,840, respectively (SI Appendix,
Fig. S2A). Other ions detected were m/z 1,850 and m/z 1,866
(SI Appendix, Fig. S2A and Fig. 2), which are consistent with the
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Fig. 1. Analysis of K. pneumoniae lipid A in vivo. Negative ion MALDI-TOF mass spectrometry spectra from: (A) BALF obtained from mock-infected animals (red
spectrum) or Kp52145-infected mice (black spectrum); (B) Kp52145 grown in LB; (C) from bacteria recovered after plating the infected lung homogenate in LB agar
plates for 24 h at 37 °C; (D) bacteria recovered after second passage of bacteria isolated from infected lung homogenate; (E ) BALF obtained from lpxO-infected
mice; (F) lpxO mutant grown in LB; and (G) bacterial loads in the tissues of infected mice (n = 5 per time point and strain). Kp52145, black symbols; 52145-ΔlpxO,
white symbols. Results are reported as log colony-forming units per gram of tissue (log cfu/g). ns, not significant (P > 0.05; one-tailed t test). In A and E, results are
representative of five indepedent extractions; in B–D and F, results are representative of extractions from 10 infected animals.
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addition of palmitate (C16) (m/z 239) to ionsm/z 1,614 andm/z 1,630,
respectively. Peaksm/z 1,630 andm/z 1,866 were detected in the lipid
A extracted from lung homogenates of mice infected with the lpxM
mutant (SI Appendix, Fig. S2B). PagP is the acyltransferase re-
sponsible for adding palmitate to Klebsiella lipid A (15). As antici-
pated, the lipid A species detected in the double mutant pagP-lpxM
grown in LB lacked palmitate (C16) and the species detected, m/z
1,614 andm/z 1,630, are consistent with four R-3-hydroxymyristoyl
primary acyl chains, and either one myristate (C14) or one
2-hydroxymyristate (C14:OH), respectively (SI Appendix, Fig. S2C).
A hallmark of K. pneumoniae lipid A expressed in vivo was
the presence of 2-hydroxymyristate (C14:OH). The presence of
2-hydroxyl fatty acids in the lipid A has been reported for Salmo-
nella enterica serovar typhimurium (C14:OH) (5, 7, 8), Pseudomonas
aeruginosa (C12:OH) (17), and Bordetella spp. (C12:OH) (18, 19).
LpxO has been identified as the oxygenase that 2-hydroxylates the
C14 or C12 acyl chains. In silico analysis of the available K. pneu-
moniae genomes revealed the presence of an ortholog of Salmo-
nella LpxO (64% identity, locus tag BN49_1127 Kp52145 genome),
which could generate the 2-hydroxymyristate found in the lipid A.
Confirming our prediction, the lipid A extracted from lung
homogenates of mice infected with the lpxO mutant, strain
52145-ΔlpxO, lacked the ions containing 2-hydroxymyristate
(C14:OH) (m/z 1,840 andm/z 1,866) and, instead, contained ionsm/z
1,824 andm/z 1,850, am/z difference of 16 from ionsm/z 1,840 and
m/z 1,866, respectively (Fig. 1E). The 52145-ΔlpxO lipid A lacked
the ion m/z 1,840 when the mutant was grown in LB (Fig. 1F).
Complementation of lpxO restored the m/z 1,840 species in the
lipid A of 52145-ΔlpxO grown in LB (SI Appendix, Fig. S3A).
To test the importance of LpxO-dependent lipid A modification
in K. pneumoniae virulence, we evaluated the ability of 52145-ΔlpxO
to cause pneumonia. Mice were infected intranasally and the bac-
terial loads in trachea, lung, and spleen homogenates were de-
termined at 24 and 72 h postinfection (Fig. 1G). Bacterial loads of
the mutant strain were lower than those of the wild type in both
the trachea and the lung (Fig. 1G). In contrast, no significant
differences were found in the spleen (Fig. 1G). Interestingly,
species lacking the 2-hydroxylated fatty acid, m/z 1,824 and m/z
1,797, were detected in the lipid A extracted from spleen ho-
mogenates (SI Appendix, Fig. S1D). Ion m/z 1,797 has been pre-
viously detected in Klebsiella lipid A and is consistent with two
glucosamines, two phosphates, four R-3-hydroxymyristoyl primary
acyl chains, and one myristate (C14) and one laureate (C12) as the
secondary acyl chains (Fig. 2) (15, 16, 20, 21).
We were keen to find in vitro conditions in which Kp52145
produces a similar lipid A pattern to that found in the lungs of
infected mice. Several growth conditions were tested (SI Appendix,
Table S1), but only when Kp52145 was grown in M9 minimal
medium with low magnesium concentration (pH 4.5) the lipid A
pattern resembled that found in vivo (SI Appendix, Fig. S3B). We
termed this medium in vivo minimal medium (VMM). Lipid A
extracted from lpxM and lpxO mutants grown in VMM contained
similar species to those observed in vivo for these mutants (SI
Appendix, Fig. S3 C and D). Complementation of lpxO restored
species m/z 1,840 and m/z 1,866 in the lipid A of 52145-ΔlpxO
grown in VMM (SI Appendix, Fig. S3E).
LpxO Characterization. The fact that the lipid A from the lpxM
mutant contained 2-hydroxymyristate both in vivo and in vitro (m/z
1,630 and m/z 1,866) strongly suggests that Klebsiella LpxO
(KpLpxO) hydroxylates the myristate (C14) on the primary
2′-linked R-3-hydroxymyristoyl group. Mass spectrometry analysis
has previously shown that the nonreducing glucosamine of
Klebsiella lipid A is substituted with only one (amide-linked)
R-3-hydroxymyristoyl group further acylated with myristate (C14)
or 2-hydroxymyristate (C14:OH) (20, 21). In good agreement,
we show that KpLpxO hydroxylated Yersinia enterocolitica O:8
myristate (C14) on the primary 2′-linked R-3-hydroxymyristoyl
group (peaksm/z 1,404 andm/z 1,813; SI Appendix, Fig. S4C) but not
the 3′-linked E. coli C14 (SI Appendix, Fig. S4D). In contrast,
and as reported previously (7, 8), Salmonella typhimurium LpxO
(StLpxO) hydroxylated the 3′-linked E. coli C14 (peak m/z 1,813)
but not Y. enterocolitica O:8 secondary acyl chains (SI Appendix,
Fig. S4 E and F). Neither Y. enterocolitca O:8 nor E. coli K12
encodes an lpxO ortholog and their lipid As do not contain
2-hydroxyl fatty acids.
Transmembrane helix prediction analysis for the KpLpxO
sequence predicts two transmembrane helices (one at each end
of the protein) with a central domain (amino acids 19–279)
containing the active site, which likely faces the cytoplasm. To
find catalytically important residues, amino acids 35–236 were
modeled based on the crystal structure of human Asp/Asnβ-
hydroxylase (Protein Data Bank, PDB code 3RCQ) and the
multiple sequence alignment shown in SI Appendix, Fig. S5A.
These residues were then compared with the known catalytically
important residues in bovine Asp/Asnβ-hydroxylase (22), which
shares ∼75% identity to human Asp/Asnβ-hydroxylase. The re-
sulting model predicts that KpLpxO has the Asp/Asnβ-hydroxylase
fold, with a typical iron-binding motif, H-X-D-X∼50-H (H155-R-D-
X44-H202 in KpLpxO), in the active site cavity (SI Appendix, Fig.
S6). The active site residues (within 4 Å from the cavity) of KpLpxO
are conserved in the multiple sequence alignment (SI Appendix, Fig.
S5B). To confirm that these residues are important for LpxO ac-
tivity, we constructed several LpxO FLAG-tagged mutants where
the conserved residues are substituted by alanine (SI Appendix,
Table S2). In contrast to wild-type LpxO FLAG tagged, none of the
LpxO mutants restored the presence of m/z 1,840 and m/z 1,866 in
the lipid A of the lpxOmutant grown in VMM (SI Appendix, Table
S2). Western blot analysis confirmed that the mutant proteins
were expressed (SI Appendix, Fig. S7). Taken together, our data
show that the 3D fold of KpLpxO likely resembles that of human
Asp/Asnβ-hydroxylase and that the active site of KpLpxO is sim-
ilar to that of bovine Asp/Asnβ-hydroxylase.
Regulation of in Vivo Lipid A Pattern. We sought to determine the
signaling networks responsible for the lipid A pattern found in
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Fig. 2. Proposed lipid A chemical structures. Proposed structures follow pre-
viously reported structures for Klebsiella (15, 16, 21) and other Gram-negative
bacteria.
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vivo. We have previously shown that the PhoPQ, PmrAB, and
Rcs systems control the loci necessary for lipid A remodeling in
K. pneumoniae (15). We asked whether any of these systems may
control the K. pneumoniae lipid A pattern in vivo. Mass spec-
trometry analysis revealed that lipid A extracted from lung ho-
mogenates of mice infected with the phoQ mutant lacked the ion
m/z 1,866 (Fig. 3A) and the other ions detected, m/z 1,824 and
m/z 1,797, were not found in lung homogenates from mice infected
with the wild type (Fig. 1A and SI Appendix, Fig. S1). In contrast,
the lipid A extracted frommice infected with either the pmrAB (Fig.
3B) or rcsB (Fig. 3C) mutants was similar to that of the wild type,
thereby suggesting that PhoPQ plays a major role in regulating
K. pneumoniae lipid A plasticity in vivo. PhoPQ also regulated the
lipid A pattern of K. pneumoniae cultured in VMM (SI Appendix,
Fig. S8). Complementation of the phoQ mutant restored the lipid
A profile to that of the wild-type strain when cultured in VMM (SI
Appendix, Fig. S8B).
To monitor whether PhoPQ controls lpxO expression in vivo,
we constructed a transcriptional fusion in which a promoterless
firefly luciferase gene (lucFF) was under the control of the lpxO
promoter region; the lpxO::lucFF fusion was then introduced
into K. pneumoniae strains. Mice were intranasally infected with
the reporter strains and the luciferase activity in lung homoge-
nates was measured. Luminescence was lower in lung homoge-
nates from mice infected with the phoQ mutant than in those
infected with the wild-type strain or any of the other regulatory
mutants (Fig. 3D). PhoPQ also controlled the expression of lpxO
in vitro because the VMM-induced increase in lpxO::lucFF ac-
tivity was only observed in the wild type and not in the phoQ
mutant (SI Appendix, Fig. S9A). Similar results were obtained
when the lpxO mRNA levels were analyzed by real-time quan-
titative PCR (RT-qPCR) (SI Appendix, Fig. S9B). The activity of
the transcriptional fusion phoP::lucFF and phoP mRNA levels
were also up-regulated in a PhoPQ-dependent manner by growing
Kp52145 in VMM (SI Appendix, Fig. S9 C and D). Complemen-
tation of the phoQ mutant restored the activities of the tran-
scriptional fusions lpxO::lucFF and phoP::lucFF to wild-type levels.
Similar results were obtained when the lpxO and phoP mRNA
levels were analyzed (SI Appendix, Fig. S9).
Klebsiella in Vivo Lipid A Pattern and Inflammatory Responses. Next,
we investigated the ability of the lipid A pattern found in vivo to
stimulate inflammatory responses. For these experiments, lipid
A was purified from Kp52145 and 52145-ΔlpxO isogenic capsule
mutants (hereafter WT* and lpxO*, respectively) to avoid the
copurification of the capsule polysaccharide with the LPS (23).
Lipid A was also purified from the lpxO complemented strain
(52145-ΔwcaK2-ΔlpxOCom; lpxO*Com). Lipid As were purified
from bacteria grown in LB or VMM. WT*VMM lipid A stim-
ulated less TNFα secretion by macrophages than WT*LB lipid A
(P < 0.01; one-way ANOVA), which induced similar levels of
TNFα than lpxO*LB (P > 0.05; one-way ANOVA). lpxO*VMM
lipid A induced more TNFα than lipid A fromWT*VMM (P < 0.01;
one-way ANOVA) (Fig. 4A). TNFα levels induced by lipid A from
lpxO*ComVMM were not signifcantly different from those induced
by lipid A from WT*VMM (Fig. 4A) (P > 0.05; one-way ANOVA).
We next assessed the activation of the NF-κB signaling cascade in
macrophages challenged with the different lipid As. Immunolocali-
zation of the NF-κB p65 subunit in macrophages revealed that the
number of positive nuclei was significantly lower in cells challenged
with WT*VMM lipid A than in those challenged with WT*LB or
lpxO*VMM lipid As, which were not significantly different (P > 0.05,
one-tailed t test; Fig. 4B). No significant differences were observed
between cells challenged with lipid A from WT*VMM or from
lpxO*ComVMM (P > 0.05, one-tailed t test; Fig. 4B). In the ca-
nonical NF-κB activation pathway, nuclear translocation of NF-κB is
preceded by phosphorylation and subsequent degradation of IκBα.
In contrast to WT*VMM lipid A, the WT*LB and lpxO*LB lipid As
triggered the degradation of IκBα (Fig. 4C). The lipid A from
lpxO*VMM induced higher degradation of IκBα than that from
WT*VMM (Fig. 4C). LPS also activates the MAPKs p38, JNK, and
p44/42 through the phosphorylation of serine and threonine residues
(24). Western blot analysis revealed thatWT*LB lipid A induced the
phosphorylation of the MAPKs (Fig. 4D). WT*VMM lipid A trig-
gered the phosphorylation of only p38 and p44/42, which were less
apparent than those triggered by the WT*LB lipid A (Fig. 4D). The
reduced activation of these inflammatory signaling cascades by the
lipid A containing the in vivo pattern was partially dependent on
the presence of the 2-hydroxylated lipid A species because the
lpxO*VMM lipid A induced higher phosphorylation of p38 and
JNK than WT*VMM lipid A (Fig. 4D). No clear differences were
observed on the induction of p44/42 phosphorylation by these two
lipid As (Fig. 4D).
Further highlighting the importance of LpxO-controlled lipid A
modification to reduce host inflammatory responses, levels of tnfα
mRNA were higher in lungs of mice infected with 52145-ΔlpxO
than in those infected with Kp52145 (Fig. 4E). At 24 h post-
infection, levels of kc mRNA were significantly different between
Kp52145 and 52145-ΔlpxO-infected mice (Fig. 4E). The levels of
kc and tnfa mRNAs found in the lungs of Kp52145-infected mice
did not change over time [P > 0.05 for comparisons for a given
cytokine (one-tailed t test)] (Fig. 4E).
Together, our findings suggest that the in vivo 2-hydroxylated
lipid A elicits a limited activation of inflammatory responses both
in vitro and in vivo.
Klebsiella in Vivo Lipid A Pattern and Resistance to Antimicrobial
Peptides. Modifications of the lipid A structure have also been
linked to pathogen protection from the onslaught of host antimi-
crobial peptides (APs) (25). To address whether the lipid A pattern
found in vivo promotes K. pneumoniae resistance to APs, bacteria
grown in either LB or VMM were compared for resistance to
β-defensin 2 (BD2). BD2 is a physiological cationic AP whose levels
in the lung increase several fold during pneumonia (26). Indeed,
Kp52145 was more resistant to BD2 when grown in VMM than in
LB (Fig. 5A). Colistin (polymyxin E) and polymyxin B are two
antimicrobials that share the interaction site with the anionic LPS
with mammalian APs (25, 27). Resistance to colistin and polymyxin
B was also promoted by growing Kp52145 in VMM (Fig. 5A). The
50% inhibitory concentrations (IC50) of BD2, colistin, and poly-
myxin B for Kp52145 were lower when K. pneumoniae was grown in
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LB (6.1 ± 0.2; 2.0 ± 0.1; and 0.9 ± 0.1, respectively) than when
grown in VMM (10.0 ± 1.2; 6.6 ± 0.2; and 2.1 ± 0.2, respectively
(P < 0.01 for comparisons for a given peptide; one-tailed t test).
LpxO-dependent lipid A modification was responsible for the in-
creased resistance observed in VMM because 52145-ΔlpxO was
more susceptible to BD2, polymyxin B, and colistin than Kp52145
(Fig. 5B). The fact that the phoQ and lpxO-phoPQ mutants were as
susceptible as the lpxO mutant to the APs tested (Fig. 5B) suggests
that Kp52145 may not activate additional PhoPQ-dependent
mechanisms of AP resistance when grown in VMM. The IC50 of
BD2, colistin, and polymyxin B for the lpxO mutant grown in
VMM (4 ± 0.2; 0.5 ± 0.1; and 1.1 ± 0.1, respectively), for the
phoQ mutant grown in VMM (3.5 ± 0.4; 0.7 ± 0.4; and 1.6 ±
0.7, respectively), and for the lpxO-phopQ mutant grown in
VMM (3.2 ± 0.4; 0.9 ± 0.4; and 1.1 ± 0.7, respectively) were
not significantly different (P > 0.05 for comparisons for a given
peptide between mutant strains; one-way ANOVA) but all of
them were significantly lower than those for Kp52145 grown in
VMM (P < 0.05 for comparisons for a given peptide between a
mutant strain and the wild type; one-way ANOVA). In con-
trast, the IC50 of BD2, colistin, and polymyxin B for the lpxO
complemented strain grown in VMM (9.5 ± 0.2; 7.5 ± 0.1; and
2.4 ± 0.1, respectively) and for the complemented phoQ mutant
grown in VMM (11 ± 3; 5.9 ± 0.4; and 3.6 ± 0.7, respectively) were
not significantly different from those for Kp52145 grown in VMM
(P > 0.05 for comparisons for a given peptide between com-
plemented strains and the wild type; one-way ANOVA).
Altogether, our findings highlight that the LpxO-mediated lipid
A modification plays an important role in K. pneumoniae resis-
tance to APs.
Klebsiella in Vivo Lipid A Pattern and Resistance to Colistin. The con-
tribution of the LpxO-dependent lipid A modification to increased
colistin resistance led us to analyze whether this occurs in the
clinically relevant K. pneumoniae carbapenem–colistin-resistant
isolates. Lipid A from these strains was extracted and analyzed to
confirm the presence of LpxO-dependent modification in carba-
penem–colistin-resistant isolates. Mass spectrometry analysis
revealed that lipid A from these isolates contained ions of m/z
1,840 and m/z 1,866 (Fig. 6A). As expected, the lipid A from
isogenic lpxOmutants contained ions ofm/z 1,824 andm/z 1,850 (a
m/z difference of 16; Fig. 6B). In contrast, the lipid A extracted
from seven strains that are carbapenem resistant but susceptible to
colistin contained ions similar to those found in the lipid A from
Kp52145 grown in LB (Fig. 6C). Further supporting the connec-
tion between LpxO-dependent lipid A modification and colistin
resistance, the minimum inhibitory concentration (MIC) to co-
listin of the colistin-resistant isolates decreased when lpxO was
mutated (SI Appendix, Table S3). Complementation of the mu-
tants increased the MIC to colistin (SI Appendix, Table S3).
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Fig. 4. In vivo lipid A pattern evokes reduced inflammatory responses.
(A) TNFα secretion by MH-S macrophages stimulated with different concen-
trations of lipid A purified from 52145-ΔwcaK2 (WT*), 52145-ΔwcaK2-ΔlpxO
(lpxO*), and 52145-ΔwcaK2-ΔlpxOCom (lpxO*Com) grown in LB (white sym-
bols) or VMM (black symbols). (B) NF-κB p65 nuclear translocation in MH-S
macrophages mock treated (CON) or stimulated with lipid As (5 μg/mL) from
52145-ΔwcaK2 grown in LB (WT*LB) and VMM (WT*VMM), 52145-ΔwcaK2-
ΔlpxO grown in VMM (lpxO*VMM), and LB (lpxO*LB), and the complemented
strain, 52145-ΔwcaK2-ΔlpxOCom, grown in VMM (lpxO*ComVMM) and LB
(lpxO*ComLB). At least 100 cells per sample and experiment were counted to
determine the number of positive nuclei. (C) Immunoblot analysis of IκBα and
tubulin levels in lysates of MH-S macrophages mock treated (CON) or stimu-
lated for 60 min with lipid As (100 ng/mL) purified from 52145-ΔwcaK2 (WT*),
52145-ΔwcaK2-ΔlpxO (lpxO*), and 52145-ΔwcaK2-ΔlpxOCom (lpxO*Com) grown
in LB or VMM. (D) Immunoblot analysis of phosphorylatedMAPKs p38, JNK, and
p44/42, and tubulin levels in lysates of MH-S macrophages mock treated
(CON) or stimulated for the indicated times (in minutes) with the indicated
lipid As (100 ng/mL). (E) kc and tnfα expressions in whole lungs of non-
infected mice (five mice) or after K. pneumoniae infections (five mice per
indicated strain and time point). Bars represent mean ± SEM; ns, not sig-
nificant (one-way ANOVA).
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Fig. 5. In vivo lipid A pattern mediates resistance to antimicrobial peptides.
(A) Kp52145 grown in LB (black symbols) or in VMM (white symbols) was
exposed to different concentrations of BD2, polymyxin B, and colistin.
(B) Different strains grown in VMM were exposed to different concentra-
tions of BD2, polymyxin B, and colistin. In A and B graphs, each point rep-
resents the mean and SD of six samples from three independently grown
batches of bacteria. In A, significant survival differences are shown (*P <
0.05; one-tailed t test) between growth media. In B, significant survival
differences are shown (*P < 0.05; one-way ANOVA) between Kp52145 and
any of the mutant strains: 52145-ΔphoQGB (phoQ), 52145-ΔlpxO (lpxO),
52145-ΔlpxO-ΔphoQGB (lpxO-phoQ).
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To explore whether colistin treatment induces the lipid A
structure found in vivo, Kp52145 grown in LB was treated with
colistin and the lipid A analyzed by mass spectrometry. The lipid
A from colistin-treated Kp52145 gave mass peaks atm/z 1,840 and
m/z 1,866 (Fig. 6D). RT-qPCR experiments showed that the levels
of phoP and lpxO mRNAs were higher in colistin-treated bacteria
than in control bacteria (Fig. 6E). PhoPQ governed colistin-trig-
gered up-regulation of phoP and lpxO because colistin-induced
changes were not observed in the phoQ mutant background (Fig.
6E). Colistin treatment up-regulated the expression of the phoP::
lucFF and lpxO::lucFF transcriptional fusions in the wild-type
background (Fig. 6F). In contrast, colistin did not up-regulate the
expression of the lpxO::lucFF transcriptional fusion in the phoQ
mutant (Fig. 6F). Complementation of the phoQ mutant restored
the colistin-triggered up-regulation of phoP and lpxO mRNA
levels and the activity the lpxO::lucFF fusion to wild-type levels
(Fig. 6 E and F).
Collectively, these results indicate that colistin promotes the
lipid A changes found in vivo in a PhoPQ-dependent manner.
Discussion
The lipid A contains a molecular pattern recognized by the in-
nate immune system thereby initiating several host defense re-
sponses. Pioneering studies demonstrated that Salmonella remodels
its lipid A under changing in vitro conditions (5, 6). The knowledge
that these modifcations fortify the outer membrane, mediate re-
sistance to Aps, and evoke limited cytokine responses in vitro (3,
10, 11) led to the assumption that these lipid A structures should
be produced in vivo and the loci needed for their biosynthesis
should be important virulence factors (3). This rationale has in-
formed studies in other pathogens including Yersinia, Bordetella,
Helicobacter, Vibrio, Francisella, and Pseudomonas (3). The panoply
of lipid A modifications include the addition of aminoarabinose,
phosphoethanolamine, amino acids, palmitate, and the removal of
phosphates and fatty acids by the action of specific phosphatases
and deacylases, respectively (1–3). The contribution of these lipid A
modifications to virulence has been established in very few cases.
Thus, a question remained of whether Gram-negative pathogens do
remodel their lipid A in vivo. In this work, by combining bio-
chemistry and genetics, we have uncovered for the first time to our
knowledge the lipid A expressed by a pathogen, K. pneumoniae,
within host tissues. Our findings suggest that these in vivo-induced
lipid A changes contribute to K. pneumoniae virulence by coun-
teracting innate immune defenses.
K. pneumoniae expresessed two 2-hydroxylated hexaacyl lipid
A species (m/z 1,840 and m/z 1,866) in the lungs of infected mice,
and we have shown that LpxO is the enzyme responsible for hy-
droxylating the C14 on the primary 2′-linked R-3-hydroxymyristoyl
group. It is noteworthy that StLpxO, one of the closest homologs
to KpLpxO, hydroxylates the C14 3′-linked R-3-hydroxymyristoyl
group fatty acid instead of the 2′-linked one (7, 8, and this work)
thereby highlighting the need of biochemical analysis to conclu-
sively assign the function of lipid A enzymes. The in vivo lipid A
pattern was lost in in vitro minimally passaged bacteria, which
emphasizes that the conditions faced by pathogens in vivo cannot
be mimicked in conventional growth media such as LB. In this
regard, a previous study from our laboratory explored whether
APs, taken as a proxy for a likely environmental cue faced by
Klebsiella in the lungs, induce lipid A changes contributing to
virulence (15). However, the only lipid A species common to those
found in vivo is the ion m/z 1,840. Data shown in SI Appendix,
Table S1 illustrate the plasticity of Klebsiella lipid A under dif-
ferent growth conditions. Only when Klebsiella was grown in
VMM, did the pathogen express the same lipid A pattern found in
vivo as characterized by ions m/z 1,840 and m/z 1,866. Interest-
ingly, the in vivo lipid A pattern was not observed in Klebsiella
grown in a standard low magnesium medium used to study lipid A
changes in other pathogens (5, 6, 28, 29). In any case, it has been
reported that Salmonella up-regulates the transcription of lpxO
when growing in low magnesium medium (9). By no means do we
claim that VMM medium recapitulates the in vivo complex mi-
croenvironment of the infected lung. Instead we hypothesize that
Klebsiella activates the same regulatory network(s) to remodel its
lipid A in the lungs and when growing in VMM. Our data support
the idea that the two-component system PhoPQ plays a major role
in this process. It is beyond the scope of this work to identify the
signal(s) sensed by Klebsiella PhoQ in vivo. Elegant structure–
function studies have demonstrated that acidic pH and APs ad-
ditively activate Salmonella PhoQ (30–32). Both signals are also
relevant in the context of Klebsiella pneumonia. Nonetheless, a
Salmonella strain carrying a PhoQ mutation rendering the protein
unable to be activated by acidic pH is as virulent as the wild type
(30). It is then plausible that the stimuli sensed by PhoQ in vivo
are APs. However, it is important to remember that sensing may
be host-compartment specific. Supporting this notion, in this work
we have shown that the in vivo-induced regulatory changes are
tissue specific because the Klebsiella lipid A pattern was different
in the lungs compared with the spleen. The fact that the lipid A
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Fig. 6. Lipid A of colistin-treated bacteria is identical to lipid A expressed by
Klebsiella in the lungs. (A) Negative ion MALDI-TOF mass spectrometry spectra
from: (A) a representative clinical isolate (no. 2608) of seven strains resistant to
colistin grown in LB; (B) its isogenic lpxO mutant; (C) a representative clinical
isolate (no. 2615) of seven strains susceptible to colistin grown in LB; and
(D) Kp52145 exposed for 1 h to colistin (1 μg/mL) in LB. (E) The transcription
levels of phoP and lpxO in colistin-treated Kp52145, 52145-ΔphoQGB (phoQ),
or 52145-ΔphoQGBCom (phoQCom) (black bars) were determined by RT-qPCR
and are shown relative to the expression levels in mock-treated bacteria (white
bars). Results represent means ± SDs. *P < 0.05 (for the indicated comparison,
one-way ANOVA); ns, P > 0.05 for the indicated comparison. (F) Luminescence
was determined for bacteria carrying the transcriptional fusions phoP::lucFF or
lpxO:lucFF exposed for 1 h to different concentrations of colistin. Results are
significantly different (**P < 0.01; one-way ANOVA) from the results for
nontreated bacteria. In A–D, results are representative of extractions from five
independent experiments.
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expressed by Klebsiella in the spleen is similar to that expressed by
the phoQ mutant in the lungs suggests that PhoPQ-regulated
systems are not required for Klebsiella survival in the spleen. A
transcriptome analysis of Klebsiella in different tissues is warranted
to shed light into tissue-induced Klebsiella adaptations.
Here, we demonstrate that the LpxO-dependent lipid A modi-
fication acts as a shield against innate immunity recognition thereby
contributing to the panoply of K. pneumoniae systems involved in
the attenuation of inflammatory responses in vitro and in vivo (33–
38). This lipid A modification also helps K. pneumoniae to coun-
teract the bactericidal action of APs, including colistin, which is one
of the few remaining therapeutic options available to treat infec-
tions caused by multidrug-resistant Klebsiella isolates. The fact that
colistin treatment induces the lipid A pattern found in vivo warrants
careful consideration on the use of this antibiotic to treat
K. pneumoniae infections.
To date, no study has linked LpxO-mediated lipid A modifi-
cation to AP resistance and therefore it will be interesting to
know whether this is also the case for other pathogens containing
2-hydroxyl fatty acids in the lipid A. If this is the case, it is rea-
sonable to anticipate the development of innovative antimicro-
bial therapeutics based on targeting LpxO. At present we can
only speculate on the molecular mechanism underlying LpxO-
dependent colistin resistance. The simplest explanation is that
the addition of a 2-hydroxyl group in a fatty acid chain stabilizes
the outer membrane. It has been argued, on the basis of the
structural similarity between lipid A and sphingolipids, that this
may increase the H bonding between neighboring LPS mole-
cules, thereby resulting in bilayer stabilization (39). Lipid A
modifications are thought to increase the stability of the outer
membrane (39). Addition of the positively charged compounds
4-aminoarabinose or phosphoethanolamine would decrease the
electrostatic repulsion between the lipid A molecules hence sta-
bilizing the bilayer. Similarly, addition of palmitate would also
stabilize the bilayer by increasing the hydrophobic and van der
Waals interactions between neighboring LPS molecules. Given
indirect support to this notion, the outer membrane of a Salmo-
nella PhoP-constitutive strain is more robust than the outer
membrane of a PhoP-defective mutant (10). Future research ef-
forts will be directed to understand LpxO-mediated AP resistance.
This work further highlights the connection between viru-
lence and antimicrobial resistance. We have shown that LpxO-
dependent lipid A modification is not only important for Klebsiella
survival in the lung but also mediates resistance to the clinically
relevant AP colistin. The connection between virulence and
antibiotic resistance has been particularly studied in the case of
Pseudomonas (40, 41). A number of bacterial regulatory genes
have been identified to influence both virulence and antibiotic
resistance including PhoPQ (40, 41). In Klebsiella, the global
regulator RamA has been recently shown to regulate not only
antimicrobial resistance systems but also virulence factors in-
cluding genes associated with LPS biosynthesis (42). It is then
tempting to speculate that part of the success of the virulent
multidrug-resistant Klebsiella clones spreading worldwide (43)
may be associated with changes of their lipid A pattern to evade
immune surveillance compared with other less virulent Klebsiella
clones. Studies are on-going to corroborate this hypothesis.
Materials and Methods
Ethics Statement. Mice were treated in accordance with the Directive of the
European Parliament and of the Council on the protection of animals used for
scientific purposes (Directive 2010/63/EU) and in agreement with the Bio-
ethical Committee of the University of the Balearic Islands. This study was
approved by the Bioethical Committee of theUniversity of the Balearic Islands
with authorization no. 1748.
Bacterial Strains and Growth Conditions. K. pneumoniae 52145 is a clinical
isolate (serotype O1:K2) belonging to the CC65K2 virulent clonal group (44,
45). The mutants 52145-ΔwcaK2, 52145-ΔphoQGB, 52145-ΔpmrAB, and
52145-ΔrcsB have been described previously (15, 46). Seven clinical isolates
that were carbapenem resistant but colistin susceptible, and seven isolates
that were both carbapenem resistant and colistin resistant were provided by
Mehmet Doymaz (Pathology/Laboratories, Saint Vincent Medical Center,
NY). Bacteria were grown in LB medium at 37 °C. When appropriate, anti-
biotics were added to the growth medium at the following concentrations:
rifampicin (Rif) 25 μg/mL, ampicillin (Amp), 100 μg/mL for K. pneumoniae
and 50 μg/mL for E. coli, kanamycin (Km) 100 μg/mL, tetracycline (Tet)
12.5 μg/mL, and chloramphenicol (Cm) 25 μg/mL. VMMmedium contains 11.3 g/L
M9 minimal salts (Sigma), 0.1% Ez Mix (w/v, Sigma), 0.4% glucose (w/v, Sigma),
and 8 μM MgSO4, buffered in 100 mM Mes (Sigma) pH 4.5.
K. pneumoniae Mutant Construction. Primers for mutant construction were
designed based on the genome sequence of K. pneumoniae 52145 (accession
no. FO834904). To obtain an lpxO mutant, two sets of primers were used to
amplify two different lpxO fragments, LpxOUP (LpxOUPF 5′-CCCAGGCG-
CAGATTGCCCAG-3′ and LpxOUPR 5′-CGGATCCGGACTCACTATAGGGGCGA-
TATTGAACGGCCGATG-3′; 748 bp), and LpxODown (LpxODOWNF 5′-CGGA-
TCCGGACTCACTATAGGGGCGGTAAATGTGGAATGGTCG-3′ and LpxODOWNR
5′-TCCGTTCACTGCGTGCCCTG-3′; 952 bp) by PCR. These fragments were
annealed at their overlapping region and amplified as a single fragment,
which was cloned into pGEM-T Easy to obtain pGEMTΔlpxO. A kanamycin
cassette was obtained as a BamHI fragment from pGEMTFRTKM (15) and was
cloned into BamHI-digested pGEMTΔlpxO to generate pGEMTΔlpxOKm. The
ΔlpxO::Km allele was PCR amplified using primers LpxOUPF and LpxODOWNR
and 1 μg of PCR product was electroporated into either Kp51245 or 52145-
ΔwcaK2 harboring the lambda-red protein-encoding plasmid pKOBEG-sacB
(47). Mutants were selected onto LB agar containing kanamycin and a
recombinant in which the wild-type allele was replaced by the mutant one and
was selected and named 52145-ΔlpxOKm and 52145-ΔwcaK2-ΔlpxOKm. The
appropriate replacement of the wild-type allele by the mutant one was con-
firmed by PCR. pKOBEG-sacB was cured by growing the strain in LB plates
without NaCl containing 10% sucrose at 30 °C. The loss of the plasmid was then
checked on LB agar containing Cm. The kanamycin cassette was excised by Flp-
mediated recombination using plasmid pFLP2 (48) and the generated mutants
were named 52145-ΔlpxO and 52145-ΔwcaK2-ΔlpxO. The 52145-ΔlpxO-phoQGB
double mutant was obtained by mobilizing pMAKSACΔphoPQGB (15) into
52145-ΔlpxO. The replacement of the wild-type allele by the mutant one was
done as previously described (15) and confirmed by PCR.
lpxO mutants in the clinical isolates were constructed by insertion-duplica-
tion. Using genomic DNA from each strain as template, an internal fragment
of the lpxO gene was PCR amplified using primers KpnIntlpxOF (5′-CCGAC-
CATTCCACATTTACC-3′) and KpnIntlpxOR (5′-TGGGCATCCTCATACCATTT-3′)
and cloned into pGEM-T Easy. The fragments were obtained by EcoRI di-
gestion and cloned into EcoRI-digested pKNOCK-Km suicide vector (49) to
obtain pKNOCK-KmintlpxO. pKNOCK-KmintlpxO plasmids were mobilized in-
to K. pneumoniae colistin resistant isolates and transconjugates were selected
after growth on LB agar supplemented with Km. Integration of the suicide
vector into lpxO locus by homologous recombination was confirmed by PCR.
To construct a pagPmutant, a kanamycin casette flanked by FRT sites was
PCR amplified using as template plasmid pKD4 (50) and primers KpnpagPF
(5′-TGTCCGGAAACGCCAGCGCGTCGTTTTCATCGACCCTTAGGTGTAGGCTGGA-
GCTGCTTC-3′) and KpnPagPR (5′-AAGTAAACTTACCGTTATTGTAGGTGCCGG-
GAATATAGGTCATATGAATATCCTCCTTAG-3′). Primers incorporate 50 nucleo-
tide homologous extensions to pagP. PCR product was purified, treated with
DpnI, and 1 μg of PCR product was electroporated into Kp51245 harboring
pKOBEG-sacB. Mutants were selected on LB agar containing kanamycin and a
recombinant in which the wild-type allele was replaced by the mutant one and
was selected and named 52145-ΔpagPKm. The appropriate replacement of the
wild-type allele by the mutant one was confirmed by PCR. pKOBEG-sacB was
cured as previously described and the kanamycin casette was excised by Flp-
mediated recombination. The generated mutant was named 52145-ΔpagP. To
confirm that pagP mutation has no polar effects, the expression of the down-
stream gene, cpsE, was analyzed by RT-qPCR as previously described (15).The
expression of cpsE by 52145-ΔpagP was similar to that by the wild-type strain.
To construct an lpxM mutant, a 2.6-kb DNA fragment encompassing lpxM
was PCR amplified using primers KpnMsbBF (5′-GGTCGACTCTAGAGGATCC-
CCTC-3′) and KpnMsbBR (5′-CTGTCTGCCGAAGCGCTGAC-3′), gel purified, and
cloned into pGEM-T Easy to obtain pGEMTKpnmsbB. An EcoRI fragment was
subcloned into EcoRI-digested pUC18 to give pUCKpnmsbB. A kanamycin re-
sistance cassette, obtained as a 1.4-kb PstI fragment from pUC-4K (Pharmacia),
was cloned into NsiI-digested pUCKpnmsbB to obtain pUCKpnmsbBGB. lpxM::
GB allele was obtained by PvuII digestion and cloned into SmaI-digested
pMAKSACB (51) to give pMAKSACKpnmsbBGB. This plasmid was electro-
porated into E. coli S17-1λpir, from which the plasmids were mobilized into
K. pneumoniae 52145. Transconjugates were selected after growth on LB
plates supplemented with Cm at 30 °C. The replacement of the wild-type allele
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by the mutant one was done as previously described (15) and confirmed by
PCR. The mutant selected was named 52145-lpxMGB.
The pagP-lpxM double mutant, strain 52145-ΔpagP-lpxMGB, was obtained
by mobilizing pMAKSACKpnmsbBGB into 52145-ΔapgP. The replacement of
the wild-type allele by the mutant one was done as previously described (15)
and confirmed by PCR.
Complementation of the phoQ Mutant. To complement the phoQ mutant, a
DNA fragment of 3.1 kb containing the putative promoter region and coding
region of phoPQ was PCR amplified using Pfu polymerase and phosphorylated
primer pair Kp52_PhoPQ_compF1 (5′-ATCCTGATGGCTGACAAGGC-3′) and
Kp52_PhoPQ_compR1 (5′-TCGGGGATAAACGGTAGTGG-3′). The fragment was
gel purified and cloned into SmaI-digested pGP-Tn7-Cm (52) to obtain pGP-Tn7-
Cm_KpnPhoPQCom. The pTSNSK-Tp plasmid, which contains the transposase
tnsABCD necessary for Tn7 transposon mobilization (52), was electroporated
into the phoQ mutant. pGP-Tn7-Cm_KpnPhoPQCom plasmid was then mobi-
lized into this strain by conjugation. Colonies were screened for resistance to
Cm and sensitivity to Ap. Because the Ap cassette is located outside of the Tn7
region on the vector, sensitivity to Ap denotes the integration of the Tn7
derivative at the attTn7 site instead of incorporation of the vector into the
chromosome. Confirmation of integration of the Tn7 transposon at the
established attTn7 site located downstream of the glmS gene was verified by
PCR as we have previously described (34). pTSNSK-Tp from the recipient strain
was cured by growing bacteria at 37 °C due to the plasmid thermosensitive
origin of replication pSC101. Plasmid removal was confirmed by susceptibility
to Tp and the strain was named 52145-ΔphoQGBCom.
Complementation of lpxO Mutants. To complement the lpxO mutant, a DNA
fragment of 1.5 kb was PCR amplified using Pfu polymerase and phos-
phorylated primers LpxOUPF and LpxoDOWNR, gel purified, and cloned into
the SmaI site of pGP-Tn7-Cm (52) to obtain pGP-Tn7-Cm_KpnLpxOCom. This
plasmid was mobilized by conjugation into lpxO mutants, strains 52145-
ΔlpxO and 52145-ΔwcaK2-ΔlpxO, containing plasmid pTSNSK-Tp to obtain
52145-ΔlpxOCom and 52145-ΔwcaK2-ΔlpxOCom, respectively. Integration of
the Tn7 was confirmed as previously described. pGP-Tn7-Cm_KpnLpxOCom
was also mobilized into the clinical isolates lpxO mutants. pTSNSK-Tp from
the recipient strains was cured by growing bacteria at 37 °C.
Klebsiella lpxO was also PCR amplified using TaKaRa polymerase and
primers LpxOUPF and LpxoDOWNR, gel purified, and cloned into pGEMT-
Easy to obtain pGEMTKplpxOCom. A fragment, containing the putative
promoter and coding region of the hydroxylase, was obtained by PvuII di-
gestion of pGEMTKplpxOCom, gel purified, and cloned into the ScaI site of
the medium copy plasmid pTM100 (53) to obtain pTMKpLpxO. Salmonella
lpxO was PCR amplified using TaKaRa and primers Salm_LpxO_compF1
(5′-AGCCGTAGTAGCCCTTCAGA-3′) and Salm_LpxO_compR1 (5′-TTTCAGGGATG-
GATTCGCCG-3′) and cloned into pGEMT-Easy to obtain pGEMTSalLpxOCom.
Subsequently a PvuII fragment was cloned into ScaI-digested pTM100 to
obtain pTMSalLpxO.
For the construction of plasmid pTMLpxOFLAG, the lpxO coding region
with its own promoter and a FLAG epitope sequence right before the stop
codon was PCR amplified using Vent DNA polymerase and primers LpxOUPF
and KpnlpxocomplFLAGR1 (5′-TTACTTGTCATCGTCGTCCTTGTAGTAAACGC-
GCTCCAGAT-3′). The fragment was phosphorylated, gel purified, and cloned
into ScaI-digested pTM100.
pTM100 derivatives were introduced into E. coli DH5α-λpir and then
mobilized into K. pneumoniae strains by triparental conjugation using the
helper strain E. coli HB101/pRK2013.
Site-Directed Mutagenesis. pTMLpxOFLAG was used as template and the
desired mutations were introduced by inverse PCR using Vent polymerase and
the following primer pairs: KpnlpxOH155F (5′-GCTCGTGCCCCCTACGCCGG-3′) and
KpnlpxOH155R (5′-GCGCGGCAGACGGCTACCGT-3′); KpnlpxOD157F (5′-GCCCC-
CTACGCCGGCTCGCT-3′) and KpnlpxOD157R (5′-ACGAGCGCGCGGCAGACGGC-3′);
KpnlpxOR164F (5′-GCCTTTGCTCTGGGCCTGGC-3′) and KpnlpxOR164R (5′-TAGC-
GAGCCGGCGTAGGGGG-3′); KpnlpxOH166F (5′-GCTCTGGGCCTGGCAACGCC-3′)
and KpnlpxOH166R (5′-AAAGGCTAGCGAGCCGGCGT-3′); KpnlpxOW188F
(5′-GCGCGCGATGGAGAAGGCGT-3′) and KpnlpxOW188R (5′-ACTGTCACG-
CTGGCCATCCA-3′); KpnlpxOE198F (5′-GCGACCTATATCGCCTATGC-3′) and
KpnlpxOE198R (5′-GTCAAACAGCACGCCTTCTC-3′); KpnlpxOH202F (5′-GCCTA-
TGCGGAAAATACCAG-3′) and KpnlpxOH202R (5′-GATATAGGTCGCGTCAAA-
CA-3′); KpnlpxOR212F (5′-GCCCTGATTCTGTTCTGCGC-3′) and KpnlpxOR212R
(5′-ATTCTCACCACTGGTATTTT-3′); and KpnlpxOD218F (5′-GCTATTGAACGGC-
CGATGCG-3′) and KpnlpxOD218R (5′-GCAGAACAGAATCAGGGCAT-3′). The
name of each mutant construct includes the wild-type residue (single-letter
amino acid designation) followed by the codon number and mutant residue
(typically alanine). Amplifications were carried out using Vent DNA polymer-
ase exactly as previously described (54). The lpxO gene was sequenced to
confirm the generated mutations.
Isolation and Analysis of Lipid A. Lipid As were extracted using an ammonium
hydroxide/isobutyric acid method (13) or the TRI Reagent method (14) and
subjected to negative ion MALDI-TOF mass spectrometry analysis. To extract
lipid A from bacteria, they were grown in 10 mL of medium until the ex-
ponential phase. Bacteria were washed once with PBS and the lipid A was
extracted from the pellet using one of the mentioned protocols. To extract
lipid A from organs, they were homogenized in 1 mL PBS, an aliquot was
used for bacterial load determination, and the rest of the homogenate was
lyophilized. BALF, obtained as previously described (55), was also lyophilized.
Dry material was then used for the lipid A extraction using the aforementioned
protocols. To analyze the samples, a few microliters of lipid A suspension
(1 mg/mL) were desalted with a few grains of ion-exchange resin (Dowex
50W-X8; H+) in a 1.5-mL microcentrifuge tube. A 1-μL aliquot of the suspen-
sion (50–100 μL) was deposited on the target and covered with the same
amount of dihydroxybenzoic acid matrix (Sigma Chemical) dissolved in 0.1 M
citric acid. Different ratios between the samples and dihydroxybenzoic acid
were used when necessary. Alternatively, lipid A was mixed with 5-chloro-2-
mercapto-benzothiazole (Sigma Chemical) [20 mg/mL in chloroform/methanol
(1:1, vol/vol)] at a ratio of 1:5. Each spectrum was an average of 300 shots. A
peptide calibration standard (Bruker Daltonics) was used to calibrate the
MALDI-TOF. Further calibration for lipid A analysis was performed externally
using lipid A extracted from E. coli strain MG1655 grown in LB at 37 °C. In-
terpretation of the negative-ion spectra is based on earlier work showing that
ions with masses higher than 1,000 gave signals proportional to the corre-
sponding lipid A species present in the preparation (56). Important theoretical
masses for the interpretation of peaks found in this study are: C14:OH, 226; C12,
182; C14, 210; and C16, 239.
LPS Purification. LPS was purified from bacteria, 52145-ΔwcaK2, 52145-ΔwcaK2-
ΔlpxO, and 52145-ΔwcaK2-ΔlpxOCom grown in 2 l of LB or VMM using the
water-phenol method. LPS was further purified by DNase, Rnase, and pro-
teinase K treatments before ethanol precipitation (57). LPS was recovered by
ultracentrifugation and the pellet was resuspended in water and lyophilized.
LPS was repurified using phenol reextraction in the presence of deoxycholate
to eliminate lipoprotein contaminants (58). This LPS did not activate the NF-
κB–dependent luciferase reported gene in HEK293 cells transiently transfected
with human TLR2 (59). Lipid A was obtained by acid hydrolysis (60).
Construction of Reporter Fusions. A DNA fragment containing the promoter
regions of the lpxO gene was amplified using primers ProLpxOF (5′-TGAAG-
GTGGAGACCTTCGTCG-3′), ProLpxOR (5′-GGAATTCCGGACAGGGAAGAATGC-
CGAAG-3′), and Vent polymerase, EcoRI digested, gel purified, and cloned into
EcoRI–SmaI-digested pGPL01 (61). This vector contains a promoterless firefly
luciferase gene (lucFF) and a R6K origin of replication. A plasmid in which
lucFFwas under the control of the lpxO promoter was identified by restriction
digestion analysis and named pGPLKpnLpxO. The plasmid was introduced into
the different Klebsiella strains used in this study by conjugation. Strains in
which the suicide vector was integrated into the genome by homologous re-
combination were selected. This was confirmed by PCR. The phoP::lucFF
transcriptional fusion has been described previously (15).
Luciferase Activity. The reporter strains were grown on an orbital incubator
shaker (180 rpm) until late log phase and, when indicated, colistin was added
and the culture incubated for 1 h more. At the end of the incubation the OD
at 540 nm was recorded. A 100-μL aliquot of the bacterial suspension was
mixed with 100 μL of luciferase assay reagent [1 mM D-luciferin (Synchem) in
100 mM citrate buffer pH 5]. Luminescence was immediately measured with
a LB9507 Luminometer (Berthold) or a Glomax 20/20 Luminometer (Prom-
ega) and expressed as relative light units (RLU)/OD540. All measurements
were carried out in quintuplicate on at least three separate occasions.
For in vivo determination of luciferase activity, groups of five mice were
infected with ∼1 × 106 cfu of each reporter strain. After 24 h, mice were killed
by cervical dislocation, and lungs were rapidly homogenized in 500 μL PBS using
an Ultra-Turrax TIO basic disperser (IKA). Serial dilutions were plated on LB-agar
with rifampin to determine the number of colony-forming units. In parallel,
100 μL of the organ homogenate was mixed with 100 μL of luciferase assay
reagent [1 mM d-luciferin (Synchem) in 100 mM citrate buffer, pH 5], and lu-
minescence was immediately measured and expressed as RLU per cfu. Control
experiments showed that homogenized lungs did not quench luminescence.
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Structural Modeling of KpLpxO. To search for related sequences and a crystal
structure that could be used as a template for modeling, the KpLpxO sequence
was used as bait to search UniProtKB and Protein Data Bank with the Basic
Local Alignment Search Tool (BLAST) at NCBI (blast.ncbi.nlm.nih.gov/Blast.cgi).
KpLpxO was also subjected to the transmembrane helix prediction server
TMHMM (www.cbs.dtu.dk/services/TMHMM/), and a homology model of the
nontransmembrane part was constructed based on the crystal structure of
human Asp/Asn β-hydroxylase isoform A (residues 562–758, PDB code 3RCQ).
MALIGN (62) in the BODIL modeling environment (63) was used to align
KpLpxO with similar sequences (SI Appendix, Fig. S5A). Human Asp/Asn
β-hydroxylase sequence was then added to the alignment, using prealigned
sequences. For modeling, all sequences, except KpLpxO and human Asp/Asn
β-hydroxylase, were deleted from the alignment (SI Appendix, Fig. S5A). A set
of 10 models was created with MODELER (64), and the model with the lowest
value of the MODELER objective function was analyzed and compared with
the crystal structure of human Asp/Asn β-hydroxylase. The quality of the final
model was assessed with various servers, such as QMEAN (65), ProSA-web (66),
andModFOLD (67). The active site cavity, and lining amino acids, was detected
with SURFNET (68). The calculations were performed with a gap sphere with a
minimum radius of 1.5 Å and maximum radius of 4.0 Å. PyMOL (version 1.4,
Schrödinger) was used to prepare pictures of the 3D model.
Murine Infection Model. Five-to-seven-week-old female CD-1 mice (Harlan)
were anesthetized by i.p. injection with a mixture containing ketamine
(50 mg/kg) and xylazine (5 mg/kg). Bacteria inoculi were prepared as pre-
viously described (35). Mice were inoculated intranasally with 20 μL of bac-
terial suspension adjusted to 107 cfu/mL. Noninfected mice were inoculated
with 20 μL of PBS. At 24 h postinfection mice were killed by cervical dislo-
cation. Tissues were rapidly dissected for bacterial load determination and
half of the lungs were immediately frozen in liquid nitrogen and stored at
−80 °C until purification of RNA was carried out.
RT-qPCR. RNA from lungs was purified exactly as previously described (35).
cDNA was obtained by retrotranscription of 1 μg of total RNA using the
M-MLV Reverse Transcriptase (Sigma). The reaction included one step to
eliminate traces of genomic DNA. A total of 50 ng of cDNA was used as a
template in a 25-μL reaction. RT-PCR analyses were performed with a Smart
Cycler real-time PCR instrument (Cepheid) and using a KapaSYBR Fast qPCR
kit as recommended by the manufacturer (Cultek). Sequences of primers
used for RT-qPCR are mKC.F (5′-GACAGACTGCTCTGATGGCA-3′) and mKC.R
(5′-TGCACTTCTTTTCGCACAAC-3′); and mTNFa.F (5′-CCACATCTCCCTCCAGA-
AAA-3′) and mTNFa.R (5′-AGGGTCTGGGCCATAGAACT-3′). The thermocycling
protocol was as follows: an initial denaturation step at 95 °C for 3 min, 40 cycles
of 95 °C/20 s, and 60 °C/30 s. RT-qPCR analyses were performed using an iCycler
real-time PCR instrument (Bio-Rad). Relative quantities of mRNAs were ob-
tained using the comparative threshold cycle (ΔΔCT) method by normalizing to
hprt1 amplified using primers mHPRT1.F (5′-AAGCTTGCTGGTGAAAAGGA-3′)
and mHPRT1.R (5′-TTGCGCTCATCTTAGGCTTT-3′).
Bacterial RNA was obtained as previously described (15). cDNA was
obtained by retrotranscription of 2 μg of total RNA using a commercial
M-MLV Reverse Transcriptase (Sigma), and random primers mixture (Quiagen).
A total of 50 ng of cDNA was used as a template in a 25-μL reaction using a
KapaSYBR Fast qPCR kit (Cultek). The thermocycling protocol was as follows;
95 °C for 3 min for hot-start polymerase activation, followed by 45 cycles of
95 °C for 15 s, and 60 °C for 30 s. SYBR green dye fluorescence was measured at
521 nm. cDNAs were obtained from three independent extractions of mRNA
and each one was amplified by RT-qPCR on two independent occasions
using primer pairs Kp52_PhoP_qPCR_F1 (5′-GCGGTTACG GATCAGGGTTT-3′)
and Kp52_PhoP_qPCR_R1 (5′-TACGTCACCAAGCCTTTCCA-3′) to analyze phoP
expression or Kp52_LpxO_F1 qPCR (5′-GACCGCTGCTTTATC GAGGT-3′) and
Kp52_LpxO_R1 qPCR (5′-CTCATCAGATGGCGTCCCAG-3′) to study lpxO ex-
pression. Relative quantities of mRNAs were obtained using the comparative
threshold cycle (ΔΔCT) method by normalizing to rpoB and tonB genes (15).
TNFα Stimulation Assay.Murine alveolar macrophages MH-S (ATCC CRL-2019)
were cultured as previously described (69). MH-S were seeded to 80% con-
fluence (1 × 105 cells per well) in 96-well tissue-culture plates and stimulated
with different concentrations of lipid A for 16 h. Supernatants were re-
covered, cell debris was removed by centrifugation, and samples were fro-
zen at −80 °C. TNFα levels in the supernatants were determined using a
commercial ELISA (eBioscience) with a sensitivity of <2 pg/mL. Experiments
were run in triplicate and repeated at least three independent times.
NF-κB p65 Staining. MH-S macrophages were seeded to 90% confluence in
24-well tissue culture plates containing a 13-mmdiameter borosilicate coverslip.
Cells were stimulated with lipid A (5 μg/mL) diluted in complete RPMI for
45 min. After stimulation, coverslips were washed twice with PBS, fixed for
15 min in 4% paraformaldehyde, and kept at 4 °C in 14 mM NH4HCl diluted in
PBS. p65 staining was carried out exactly as previously described (33). Samples
were analyzed using a fluorescence microscope Leica DM6000 and images
were taken with a Leica DFC350FX camera. Experiments were run in triplicate
and repeated at least three independent times.
Immunoblotting. MH-S cell extracts were obtained as previously described
(69). Proteins were resolved by standard 10% SDS/PAGE and electroblotted
onto nitrocellulose membranes. Membranes were blocked with 4% (wt/vol)
skim milk in TBST and protein bands were detected with specific antibodies
using chemiluminescence reagents and a GeneGnome chemiluminescence
imager (Syngene). Immunostainings for IκBα and to assess phosphorylation
of p38, p44/42, and JNK MAPKs were performed using polyclonal rabbit,
anti- IκBα, anti-phospho-p38 antibody, anti-phospho-p44/42, and anti-
phospho-JNK antibodies, respectively (all used at 1:1,000; Cell Signaling).
Blots were reprobed with polyclonal antibody anti-human tubulin (1:3,000;
Sigma) to control that equal amounts of proteins were loaded in each lane.
Experiments were repeated three independent times.
To detect the levels of LpxO FLAG-tagged proteins, bacterial cell extracts
were preparared in SDS sample buffer. The protein concentration was de-
termined using the BCA Protein Assay Kit (Thermo Scientific). A total of 80 μg of
proteins was separated on 4–12% SDS/PAGE and semidry electrotransferred
onto a nitrocellulose membrane. Membrane was blocked with 4% skimmilk in
PBS and stained using anti-Flag antibody (1:2,000; Sigma) following the in-
structions of the supplier.
Antimicrobial Peptide Susceptibility Assay. Antimicrobial peptide susceptibility
was determined exactly as previously described (15). All experiments were done
with duplicate samples on at least four independent occasions. The 50% in-
hibitory concentration of AP (IC50) was defined as the concentration producing
a 50% reduction in the colony counts compared with bacteria not exposed to
the antibacterial agent. Following guidelines of the National Institutes of
Health Chemical Genomics Center (www.ncats.nih.gov/ncgc), IC50 of a given AP
was determined from dose–response curve data fit using a standard four-
parameter logistic nonlinear regression analysis. Dose–response experiments
were done on four independent occasions. Results are reported as mean± SEM.
Statistical Analysis. Statistical analyses were performed using one-way analysis
of variance (ANOVA) with Bonferroni contrasts or the one-tailed t test or, when
the requirements were not met, by the Mann–Whitney u test. P < 0.05 was
considered statistically significant. The analyses were performed using Prism4
for PC (GraphPad Software).
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